|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
86618 JD HEALTH-R
Nominal 
26.250 +0.300 (+1.156%) | 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | |
| Turnover | 53,529,941 | 14.536% | 46,736,150 | 30,682,267 | 19,382,568 | 10,842,140 |
| Cost of Sales | (41,664,605) | 13.082% | (36,844,642) | (23,484,985) | (14,465,270) | (8,029,868) |
| Gross Profit | 11,865,336 | 19.955% | 9,891,508 | 7,197,282 | 4,917,298 | 2,812,272 |
| 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | (69,859) | -28.862% | (98,202) | (38,352) | (17,539,975) | (1,264,989) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | (70,757) | -26.873% | (96,759) | (94,165) | (77,024) | 0 | |
| Profit / (Loss) before Taxation | 2,693,348 | 287.082% | 695,809 | (901,491) | (17,072,141) | (834,700) | |
| Taxation | (550,468) | 76.105% | (312,580) | (171,327) | (162,756) | (137,105) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (1,039) | -66.741% | (3,124) | (689) | 534 | 0 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 2,141,841 | 463.487% | 380,105 | (1,073,507) | (17,234,363) | (971,805) | |
| 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (1,939,547) | 126.803% | (855,167) | (451,570) | (145,700) | 3,719 |
| Depreciation & Amortisation | 227,458 | 61.689% | 140,676 | 63,169 | 27,221 | 7,423 |
| Directors' Emoluments | 418,439 | -37.062% | 664,846 | 1,062,758 | 296,370 | 19,345 |
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| EPS (cts) | 69.000 | 475.000% | 12.000 | -35.000 | -780.000 | -45.000 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | -- |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | 1.474 | -- | 1.901 | 1.109 | 1.675 | 0.191 |
| NBV per share ($) | 15.479 | -- | 14.082 | 12.475 | 12.326 | -- |
| Remarks: | Real time quote last updated: 28/11/2024 11:02 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 2,037,182 |
| %Change | 30.475% |
| EPS / (LPS) | RMB 0.650 |
| NBV Per Share (¥) | RMB 16.344 |